Pharming Group N.V.
PHAR
$13.40
-$0.879-6.16%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | 25.82% | 14.10% | 34.97% | 30.66% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 25.82% | 14.10% | 34.97% | 30.66% | |
| Cost of Revenue | 12.42% | 71.58% | 39.43% | 105.79% | |
| Gross Profit | 27.43% | 8.58% | 34.45% | 22.71% | |
| SG&A Expenses | 17.93% | -18.71% | 8.15% | 22.24% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -102.74% | -100.69% | -7.55% | 40.41% | |
| Total Operating Expenses | 16.78% | -16.13% | 9.25% | 27.92% | |
| Operating Income | 197.69% | 176.70% | 80.22% | -19.39% | |
| Income Before Tax | 11,898.33% | 428.80% | -101.77% | 0.30% | |
| Income Tax Expenses | 118.39% | 249.73% | -43.98% | 6.49% | |
| Earnings from Continuing Operations | 473.56% | 191.55% | -192.34% | -1.97% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 485.39% | 191.55% | -192.34% | -1.97% | |
| EBIT | 197.69% | 176.70% | 80.22% | -19.39% | |
| EBITDA | 465.16% | 351.07% | 91.88% | 8.51% | |
| EPS Basic | 477.78% | 184.78% | -190.00% | 0.00% | |
| Normalized Basic EPS | -300.00% | 135.19% | 99.39% | -- | |
| EPS Diluted | 466.67% | 176.09% | -220.00% | 0.00% | |
| Normalized Diluted EPS | -300.00% | 135.19% | 99.39% | -- | |
| Average Basic Shares Outstanding | -0.37% | 9.63% | 2.52% | 1.97% | |
| Average Diluted Shares Outstanding | -0.37% | 9.63% | 2.52% | 1.97% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |